Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers

The purpose of this study is to assess the safety and tolerability of escalating doses of CSL112 after single intravenous infusions in healthy volunteers and to measure the pharmacokinetics of CSL112 after single intravenous infusions in healthy volunteers.

Inclusion Criteria:

• Healthy males and females aged 18 years to less than 55 years
• Body weigh 45 kg or greater

Exclusion Criteria:

• Evidence of a clinically significant medical condition, disorder or disease
• Evidence of clinically relevant abnormal laboratory test result
• Evidence of history of alcohol or substance abuse